...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical rheumatology >The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si
【24h】

The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si

机译：与其他肿瘤坏死因子-α抑制剂相比，Golimalab的持续性在日常临床实践中治疗类风湿性关节炎，强直性脊柱炎和银屑病性关节炎：从生物学疾病改性抗腹性药物治疗的术患者患者的观测结果 - biorx.si.

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To assess the persistence of golimumab and other tumour necrosis factor-alpha inhibitors (TNFis) in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Slovenia. We analysed prospectively the collected data of all patients treated with golimumab and other TNFis from 1 January 2010 to 31 July 2018 from the mandatory national BioRx.si registry. We assessed the treatment persistence stratified by treatment type, indication and prior exposure to bDMARDs using the Kaplan-Meier method and Cox proportional regression hazards' models adjusted for the well-appreciated confounders. We also assessed its effectiveness at 1 year after the initiation of therapy. During the 7-year observation period, 24 Slovenian rheumatologists from eight centres contributed data on 368, and 1654 patients treated for 849, and 3321 person-years with golimumab and other TNFis, respectively. The overall proportions of RA, AS and PsA patients being persistent on golimumab vs. other TNFis at 2 years after starting the therapy did not differ significantly and were 53%, 67% and 59% vs. 47%, 65% and 59%, respectively. The crude and adjusted hazard ratios for golimumab discontinuation did not differ significantly between bDMARD-naive and bDMARD-experienced patients for any of the indications. In contrast, bDMARD-experienced AS and PsA patients treated with other TNFis were significantly more likely to discontinue treatment. The persistence of golimumab in patients with RA, AS and PsA in Slovenia was comparable with its persistence in more affluent Western European countries. We observed a better persistence of golimumab compared to other TNFis in bDMARD-experienced AS and PsA patients.
机译：评估斯洛文尼亚类风湿性关节炎（RA），强直性脊柱炎（AS）和银屑病关节炎（PSA）患者中的Golimalab和其他肿瘤坏死因子-αβ抑制剂（TNFI）的持续性。我们预期分析了从2010年1月1日至2018年7月31日从强制性国家Biorx.SI注册管理机构治疗的所有患者的收集的所有患者的收集数据。我们使用Kaplan-Meier方法和Cox比例回归危险的模型评估了通过治疗类型，指示和前后暴露于BDMard的治疗持久性。我们还在治疗启动后1年内评估其有效性。在7年的观察期间，来自八个中心的24位斯洛文尼亚风湿病学家在368名中贡献了数据，1654名患者分别治疗了849名和3321人，分别用Golimalab和其他TNFIS。 RA的总体比例，AS和PSA患者在开始治疗后2年在Golimalab与其他TNFIS上持续存在的患者没有显着差异，53％，67％和59％，6.％，65％和59％，分别。 Golimalab停止的原油和调整的危险比在BDMard-Naive和BDMard型患者之间没有显着差异，适用于任何适应症。相比之下，与其他TNFIS治疗的BDMARD经验丰富的AS和PSA患者显着不断停止治疗。斯洛文尼亚患者的Golimialab患者的持续性与其在更富裕的西欧国家的持续存在方面相当。与BDMARD经验丰富的患者和PSA患者的其他TNFI相比，我们观察了Golimalab的更好持久性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号